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To the editor
New oral antiplatelet drugs (prasugrel, ticagrelor) are rec-
ommended in the current European Society of Cardiology
guidelines for the management of patients presenting with
ST-segment elevation myocardial infarction (STEMI) [1].
However, in many STEMI hospital networks administra-
tion of a 600-mg clopidogrel loading dose before or during
transfer to cathlab (including in ambulance administration)
is a standard of care, since this strategy has been imple-
mented for many years. Early administration of the drug
may enhance antiplatelet effects of clopidogrel at the time
of primary percutaneous coronary intervention (PCI), in
comparison to the administration in the cathlab. On the
other hand, the response to clopidogrel in patients with
STEMI, especially in patients with hemodynamic com-
promise is impaired. Prasugrel and ticagrelor are more
potent antiplatelet drugs, with faster and more profound
antiplatelet effect. These agents are preferred over clopi-
dogrel, if not contraindicated, in patients with STEMI since
both are superior in comparison to clopidogrel in terms of
the reduction of ischemic events [2, 3]. However, intro-
duction of prasugrel and ticagrelor may need to change
STEMI network logistics since those new drugs are
predominantly administered in the cathlab, but not in
ambulances or in non-PCI centers before transportation [4].
In our high-volume primary PCI center, early (before
transfer to cathlab) administration of acetylsalicylic acid,
unfractionated heparin and a 600-mg clopidogrel loading
dose has been a well-established standard of treatment
from many years. In-cathlab administration of antiplatelet
drugs was a rare strategy so it was necessary to reorganize
STEMI network for new antiplatelet drugs introduction in
daily practice. An observational, prospective registry was
designed to describe the implementation of new oral anti-
platelet drugs in our network. First 100 consecutive STEMI
patients (no exclusion criteria) admitted to our center after
introduction of prasugrel and ticagrelor were enrolled.
Registry was focused on antiplatelet therapy including type
of drug, moment of administration, time from administra-
tion to PCI. Data on reason for the administration of
clopidogrel instead of new drugs was also collected.
Additionally, platelet aggregation inhibition was assessed
at the time of PCI (guide wire introduction) with Platelet-
works Aggregation Kits (Helena Laboratories, Beaumont,
TX, USA) [5]. The registry analyzed the current clinical
practice and did not modify patients diagnostics and
treatment.
A total of 100 consecutive STEMI patients entered the
registry. Clinical characteristics of patient population are
presented in Table 1. Registry represents real life STEMI
population including elderly patients and patients in car-
diogenic shock. Acetylsalicylic acid was administered
before transfer to cathlab in all patients. New oral anti-
platelet drugs were given after cathlab admission before or
during coronary angiography only in 15 out of 100 patients
(13 patients treated with a 60-mg prasugrel loading dose; 2
patients treated with a 180-mg ticagrelor loading dose). In
the remaining 85 patients a 600-mg clopidogrel loading
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dose was given before (80 patients) or after admission to
the cathlab (5 patients). Reasons for the administration of
clopidogrel instead of new antiplatelet drugs are presented
in Fig. 1. The contraindications for prasugrel/ticagrelor
were present in 18 patients. In 65 patients the main cause of
new therapy introduction failure was clopidogrel loading
dose given before transfer to the cathlab (according to
earlier everyday practice). The time from the administra-
tion of loading dose to PCI was significantly longer in
patients treated with clopidogrel than with new antiplatelet
drugs (median [IQR]: 75 [60–110] vs 15 [12.5–20] min;
p \ 0.0001). There was no significant difference in the
platelet aggregation inhibition at the time of PCI between
groups. However, a trend towards higher inhibition in
clopidogrel pretreated patients was observed (median
[IQR]: 55 % [43–63] vs 48 % [41–51]; p = 0.08). PCI was
performed in 97 % of patients with aspiration thrombec-
tomy in more than half of patients, and with the wide range
of stents types used (Table 1). Abciximab was adminis-
tered during PCI in 28 patients (in three patients treated
with prasugrel) after platelet function assessment.
Our data showed that introduction of new antiplatelet
drugs may be slowed down by well established strategy of
early clopidogrel loading dose administration. In such
circumstances, the administration of prasugrel/ticagrelor on
top of clopidogrel may be an option since all those drugs
competitively block one receptor (known main mode of
action) but clinical data on the safety of such approach are
relatively limited. PLATO study has included patients
pretreated with clopidogrel and ticagrelor administration is
Table 1 Baseline characteristics, concomitant medications and
interventional treatment details
Variable STEMI patients
(n = 100)
Males 69/100
Age [years] 62 [56–73]
Age C75 years 23/100
Age C80 years 14/100
Diabetes mellitus 29/100
Arterial hypertension 50/100
Previous stroke/TIA 6/100
Previous myocardial infarction 9/100
Previous PCI 9/100
Cardiogenic shock on admission 10/100
Anterior wall infarction 43/100
Stent thrombosis 0/100
PCI 97/100
TIMI 3 flow grade after PCI 93/100
Aspiration thromectomy 52/97
Stent 90/97
DES 45/90
Mesh-covered (MGuard) stent 14/90
Self-expandable (Stentys) stent 4/90
BMS (non MGuard, non Stentys) 27/90
Values are presented as number of patients or medians [inter-quartile
range]
BMS bare metal stent, DES drug eluting stent, PCI percutaneous
coronary intervention, TIA transient ischemic attack, TIMI throm-
bolysis in myocardial infarction
Fig. 1 Reasons for the
treatment with clopidogrel
instead of new antiplatelet drugs
(prasugrel/ticagrelor). LD
loading dose, TIA transient
ischemic attack
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recommended by current STEMI Guidelines also in clop-
idogrel pretreated patients [1, 2]. However, the assessment
of ticagrelor administration on top of clopidogrel was not
the primary objective of PLATO study. The clinical evi-
dence of prasugrel administration in clopidogrel pretreated
patients is weaker and it is based on platelet reactivity
studies (not powered for safety) [3, 6, 7]. Nevertheless, the
administration of new antiplatelet drugs in clopidogrel
pretreated is gaining popularity in clinical practice. The
time from initial STEMI diagnosis to primary PCI is still
important problem of reperfusion treatment strategy in
real-life. This also causes the delay from STEMI diagnosis
to new antiplatelet drugs administration in the cathlab. In
our registry clopidogrel was administered more than 1 h
earlier than prasugrel/ticagrelor what may influence the
platelet inhibition at the time of PCI despite more rapid
action of new antiplatelet drugs. Moreover, the response to
antiplatelet drugs in patients with STEMI may be delayed
not only for clopidogrel but also for new oral antiplatelet
drugs. However, there is no data on comparison of those
two strategies (early clopidogrel vs in cathlab prasugrel/
ticagrelor loading dose) in large scale clinical trials. In the
networks with established strategy of early clopidogrel
administration, switch for early new oral antiplatelet drugs
may be an option but there is no clinical data on safety and
efficacy of such approach (the ATLANTIC (STEMI) and
ACCOAST (NSTEMI) trials are ongoing). That strategy of
early platelet inhibition has been described with abciximab
and showed benefit in high-risk patients [8, 9]. On the other
hand, in-cathlab drugs administration may play important
role when urgent surgery is required but this is a very rare
scenario in STEMI patients. In some STEMI patients
prasugrel and/or ticagrelor are contraindicated. For those
patients early risk stratification should be performed just
after STEMI diagnosis since clopidogrel administration
before transfer may be a valuable option if new drugs are
contraindicated. Our data has important limitation includ-
ing: 1/low number of patients, but we have focused on first
group of patients after new drug introduction to define
logistics problems and upgrade the implementation process
(currently the penetration of prasugrel/ticagrelor is about
30 %); 2/registry design which reduces the value of platelet
function analysis, but the study was conducted to observe
real-life clinical practice.
In conclusion, initiation of new oral antiplatelet drugs in
STEMI networks needs to change the treatment logistics
since early clopidogrel administration is established strat-
egy for most of STEMI patients in daily practice. Tailored
antiplatelet therapy approach is necessary since as of today
three oral P2Y12 antagonists with different contraindica-
tions are available. Despite results of large scale clinical
trials there are still some gaps in evidence concerning new
antiplatelet drugs usage in real-life STEMI patients in daily
practice. This includes: usage of new antiplatelet drugs on
top of clopidogrel loading dose; optimal antiplatelet treat-
ment choice for early administration when transfer for
primary PCI is necessary; optimal antiplatelet treatment
strategy for patients after stroke/TIA, patients with need for
oral anticoagulation.
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